



Peripheral T-cell Lymphoma: From Biological Research to New Therapies

Guest Editors:

Dr. Shingo Nakahata

Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki, Japan

Dr. Kazuhiro Morishita

Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, 889-1692 Miyazaki, Japan

Deadline for manuscript submissions:

closed (15 May 2023)

Message from the Guest Editors

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas (NHL) that originates from mature T-cells, including PTCL, not otherwise specified (PTCL-NOS), anaplastic large T-cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), NK/T-cell lymphoma, and adult T-cell leukemia/lymphoma (ATLL). PTCL is generally aggressive and has a poorer prognosis than diffuse large B-cell lymphoma. Genomic analyses of some types of CTCL such as ATLL, ALCL, and PTCL-NOS have been performed so far, and the involvement of important somatic gene alterations including T-cell receptor signaling pathways has been clarified. Furthermore, the relationship between genetic mutations and prognosis and prediction of the effectiveness of anticancer drug treatment have been clarified. However, most PTCL are generally not curable and thus prevention of disease progression and development of new treatments are urgently needed. For this Special Issue, we encourage the submission of original research articles and reviews on any aspect of PTCL, including critical signaling pathways, host immune responses, and novel targeted therapies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)